Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma
Open Access
- 15 July 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (14), 3671-3681
- https://doi.org/10.1158/1078-0432.CCR-19-3925
Abstract
Purpose: Resistance to anti-PD1-based immune checkpoint blockade (ICB) remains a problem for the treatment of metastatic melanoma. Tumor cells as well as host myeloid cells can express the immune checkpoint ligand CD155 to regulate immune cell function. However, the effect of tumor CD155 on the immune context of human melanoma has not been well described. This observational study characterizes tumor CD155 ligand expression by metastatic melanoma tumors and correlates results with differences in immune cell features and response to ICB. Experimental Design: Pretreatment tumor specimens, from 155 patients with metastatic melanoma treated with ICB and from 50 patients treated with BRAF/MEK-directed targeted therapy, were assessed for CD155 expression by IHC. Intratumor T-cell features were analyzed using multiplex-immunohistofluorescence for CD8, PD1, and SOX10. Correlations were made between CD155 tumor level and bulk tumor RNA sequencing results, as well as clinical RECIST response and progression-free survival. Results: High pretreatment CD155 tumor levels correlated with high parenchymal PD1(+)CD8(+)/CD8(+) T-cell ratios (PD1(tR)) and poor response to anti-PD1 therapy. In PDL1 negative tumors, high CD155 tumor expression was associated with patients who had poor response to combination anti-PD1/CTLA4 therapy. Conclusions: Our findings are the first to suggest that tumor CD155 supports an increase in the fraction of PD1(+)CD8(+) T cells in anti-PD1 refractory melanoma tumors and, further, that targeting the CD155 pathway might improve response to anti-PD1 therapy for patients with metastatic melanoma.Funding Information
- National Health and Medical Research Council (1138757)
- NH&MRC (1159655, 1120887)
- NH&MRC (1078671)
- NH&MRC (1132519)
- CCQ (1157048)
This publication has 42 references indexed in Scilit:
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunityNature, 2015
- TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patientsJCI Insight, 2015
- PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L1 clinical trialsPigment Cell & Melanoma Research, 2014
- Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN ActivationCancer Discovery, 2014
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff OptimizationPLOS ONE, 2012
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene ClustersOMICS: A Journal of Integrative Biology, 2012
- Cutadapt removes adapter sequences from high-throughput sequencing readsEMBnet.Journal, 2011
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- REporting recommendations for tumour MARKer prognostic studies (REMARK)British Journal of Cancer, 2005